MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Clinical Trials / Study: Artificial pancreas outperforms pump therapy

Study: Artificial pancreas outperforms pump therapy

September 18, 2015 By Fink Densford Leave a Comment

Diabetes

Data from 2 new studies of closed-loop artificial pancreas indicates the device outperformed sensor-augmented pump therapy treatment for patients with Type 1 diabetes.

The findings were presented September 17 at the European Association for the Study of Diabetes 2015 meeting in Stockholm, Sweden, and published in the New England Journal of Medicine.

After 12-weeks being treated with the artificial pancreas, patients showed improved glucose control, reduced hypoglycemia and, in adults, lower glycated hemoglobin levels when compared to control therapies, according to the study.

The 2 studies examined 58 patients, 33 adults and 25 children, with type 1 diabetes over 12 weeks. Patients received treatment with an “artificial beta cell”, otherwise known as a closed-loop artificial pancreas, for a 12-week period, and treatment with a sensor-augmented insulin pump for a similar period. The devices were used at home under what the researchers called “free-living” conditions.

The studies found that with the closed-loop system, glucose levels were in the target range 11% more often than with the control therapy.

In children and adolescents, the closed-loop system provided 24.7% more time in the target glucose range.

“Our main aim was to be able to show that closed-loop application works in the day and night period, especially in the long term, and without supervision….We are now at a stage where we’ve shown that prolonged 3-month, day/night use of closed-loop control in adults is feasible, and 3-month overnight control in children is feasible,” lead investigator Dr. Hood Thabit of the U.K.’s University of Cambridge told Medscape Medical News.

The study did not use a “bionic pancreas,” which uses both insulin and glucagon, but instead used a “beta cell” artificial pancreas which used only insulin.

Filed Under: Clinical Trials, Diabetes Tagged With: New England Journal of Medicine

In case you missed it

  • Medtronic faces patent lawsuit over CoreValve tech
  • Orpyx launches sensory insoles with patient monitoring
  • Ortho devicemakers Hensler and Tobra face off in patent lawsuit
  • House bill asks CMS to cover breakthrough devices for Medicare patients
  • Empirical Spine completes enrollment in LimiFlex pivotal trial
  • MolecuLight wins FDA clearance for handheld imaging device
  • Medical device tax will cost 20,000 jobs, report says
  • W.L. Gore officials think they can spur insulin delivery system innovation
  • EPA moves closer to stricter regulations on medtech ethylene oxide sterilization
  • 3DBio Therapeutics wins FDA rare pediatric disease designation for outer ear reconstruction
  • CryoLife wins CE Mark for E-nya thoracic stent graft
  • Edwards projects $5 billion in sales for 2020
  • SPR Therapeutics announces 1000th placement of nerve stimulation device
  • The best places to work for medtech sales reps
  • DePuy Synthes issues urgent field safety notice for USS II Polyaxial 3D heads
  • Haemonetics (HAE) launches SafeTrace Tx in North America
  • Vicarious Surgical wins FDA breakthrough designation for surgical robot

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS